Is It Possible to Prevent Bone Loss in Young Women Treated with Luteinizing Hormone-Releasing Hormone Agonists?
article
OA: closed
CC0
⤵ 49 in-corpus citations
Abstract
Recent studies have shown that treatment with the LHRH agonist nafarelin gives symptomatic and objective relief to women with endometriosis. Such a treatment, however, results in increased bone turnover and loss of bone mass. In the present study 17 women with endometriosis were treated with 400 mg nafarelin combined with 1.2 mg norethisterone (NET) for 6 months, followed by 6 months with only 1.2 mg NET. The data were compared to data from a previously published study of 9 women treated for 6 months with 400 mg nafarelin alone, followed by 6 months without treatment. In the group treated with nafarelin plus NET the biochemical parameter of bone resorption (fasting urinary hydroxyproline) remained virtually unchanged, compared to a highly significant increase in the nafarelin-treated group. Estimates of bone formation (serum alkaline phosphatase and plasma bone Gla protein) increased in the nafarelin plus NET group, but to only a minor extent compared to those in the nafarelin group. In addition, bone mineral in the forearm, the spine, and the total skeleton remained virtually unchanged in the group treated with nafarelin plus NET, compared to the bone loss of 2-6%/6 months in the nafarelin group. We conclude that addition of NET to nafarelin treatment of endometriosis seems to have a bone-sparing effect.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
Cited by (49)
- Use of gonadotropin-releasing hormone agonists for ovarian preservation in patients receiving cyclophosphamide for systemic lupus erythematosus: A meta-analysis 2022
- Low-dose add-back therapy during postoperative GnRH agonist treatment 2016
- Effects of different add-back regimens on hypoestrogenic problems by postoperative gonadotropin-releasing hormone agonist treatment in endometriosis 2016
- Clinical Aspects of Endometriosis 2010
- Hormone therapy for endometriosis and surgical menopause 2009
- Hormone therapy for endometriosis and surgical menopause 2006
- GnRH analogs: Options for endometriosis-associated pain treatment 2006
- GnRH agonist and antagonist: Options for endometriosis pain treatment 2006
- Use of a gonadotropin‐releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus 2005
- Long-term effects on bone mineral density and bone metabolism of 6 months’ treatment with gonadotropin-releasing hormone analogues in Japanese women: comparison of buserelin acetate with leuprolide acetate 2005
- One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double-blind trial 2004
- HRT as add-back therapy 2002
- Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up 2000
- Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy (“draw-back” therapy) 2000
- Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? 1999
- GnRH analogueによる子宮内膜症治療における結合型エストロゲンを用いたadd-back療法の検討 1999
- The Effect of Gonadotropin-Releasing Hormone Agonist on Type I Collagen C-Telopeptide and N-Telopeptide: the Predictive Value of Biochemical Markers of Bone Turnover 1998
- GnRH agonists and add‐back therapy: is there a perfect combination? 1998
- Endometriosis and Pelvic Pain 1998
- Leuprolide Acetate Depot and Hormonal Add-Back in Endometriosis: A 12-Month Study 1998
- Intermittent etidronate partially prevents bone loss in hirsute hyperandrogenic women treated with GnRH agonist 1997
- Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists 1997
- A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone 1997
- Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment 1996
- Bone-sparing properties of oral contraceptives 1996
- Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment. 1996
- Reduction of bone mineral density by gonadotropin‐releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration 1996
- Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis 1996
- Do Progestogens and Progesterone Reduce Bone Loss? 1996
- Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin 1995
- Evidence that the loss of bone mass induced by GnRH agonists is not totally recovered 1995
- Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone “add-back” therapy 1995
- CALCIUM, ESTROGEN, AND PROGESTIN IN THE TREATMENT OF OSTEOPOROSIS 1994
- Goserelin (Zoladex) and the skeleton 1994
- Nafarelin therapy in endometriosis: Long-term effects on bone mineral density 1994
- An alternative to hysterectomy? GnRH analogue combined with hormone replacement therapy 1993
- Hormone Treatment Related Bone Mineral Content Changes in Japanese Women with Endometriosis 1993
- Medical management of endometriosis 1993
- 9 Endometriosis: Medical therapy 1993
- Changing concepts of medical treatment of endometriosis 1993
- Tamoxifen in the rat prevents estrogen-deficiency bone loss elicited with the LHRH agonist buserelin 1992
- Gonadotropin-releasing hormone agonists: Strategies formanaging the hypoestrogenic effects of therapy 1992
- A randomized double blind placebo controlled trial of the effects on bone metabolism of the combination of nafarelin acetate and norethisterone 1992
- Gonadotropin-releasing hormone analogs: Update onnew findings 1992
- Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. 1992
- Gonadotropin releasing hormone agonist treatment for severe menorrhagia in patients with contraindications to surgery 1992
- Severe endometriosis treated with gonadotrophin releasing hormone agonist and continuous combined hormone replacement therapy 1992
- Preventive effects of clomiphene citrate on estrogen-deficiency osteopenia elicited by LHRH agonist administration in the rat 1991
- Vitamin D metabolites – relation to age, menopause and endometriosis 1990
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:12:10.587122+00:00
- unpaywall
- last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0
· commercial use OK